Pharma Intelligence, Simplified

Data updated: Mar 10, 2026

SHORLA ONCOLOGY

Oncology

Pharma

SHORLA ONCOLOGY is a pharmaceutical company focused on Oncology. Key products include IMKELDI.

2024

Since

1

Drugs

-

Trials

1

Approved (2yr)

Key Drugs

imatinib mesylate

BCR-ABL tyrosine kinase 7 indications · 2024

Recent Activity

IMKELDI 2024-11-22

Type 3 - New Dosage Form

SEC Filings ProEarly access

Loading...

Therapeutic Focus

Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5

Oncology 100%

1 drugs

Pipeline Strength ProEarly access

Loading...

Competitors ProEarly access

Pfizer big-pharma

Novartis big-pharma

Merck big-pharma

Baxter specialty

AbbVie big-pharma